CompletedNot Applicable

Automated Oxygen Titration During Walking in Patients With Lung Fibrosis (OXYWILD)

Denmark29 participantsStarted 2024-06-20

Plain-language summary

Fibrotic lung disease is a group of severe scarring lung diseases with a dismal prognosis, often leading to respiratory failure and need for oxygen treatment. The symptom burden is often extremely high with dyspnea at rest and increasing dyspnea with exertion. Patients will often need more oxygen during activity thus repeatedly adjustments of oxygen flow rates are required to target an acceptable saturation at rest and during activities. This is impractical and can lead to an undesirable focus on oxygen levels as well as reduced use of the oxygen treatment in everyday life. There is an urgent need for oxygen equipment that is easy to use to help patients live a life with fever symptom-related restrictions. Closed Loop Oxygen Titration (CLOT) is a new type of optimized oxygen treatment, which automatically adjusts the oxygen flow rate to the exact amount needed for the patient. The CLOT has already been tested and found useful in patients with other lung diseases, however it has not yet been tested in an isolated group of patients with fibrotic lung disease. The goal of this clinical trial is therefore to study if automatically adjusted oxygen delivery can be useful for patients with fibrotic lung disease who needs oxygen treatment during activity. The main questions aimed to be answered are: Will participants experience less breathlessness during walking, when the oxygen supply is individually adjusted to maintain an acceptable level of oxygen saturation? Our hypotheses are that automatically adjusted oxygen dose during walking will results in less breathlessness compared to the usual fixed dose of oxygen. Furthermore, that participants will walk longer and maintain a better oxygen saturation during a walking test when offered automatically adjusted oxygen dose. Participants will perform two walking tests with both automatically adjusted and fixed dose oxygen in random order, and the difference in sensation of breathlessness will be compared between the two tests.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Verified diagnosis of fibrotic interstitial lung disease * Desaturation during a recent (6 months) 6-minute walk test below 88% on atmospheric air or during an incremental shuttle walking test * Able to walk at least 50 meters * Self-reported stable respiratory symptoms in the previous 2 weeks * Age ≥ 18 years * Cognitively able to understand and participate in the study * Written informed consent Exclusion Criteria: * Long term oxygen treatment * A pulmonary or cardiac condition other than fibrotic interstitial lung disease limiting exercise performance * Unstable heart condition or symptomatic stenotic valve disease * Any physical condition limiting exercise performance. * Smoking the previous 24 hours * Pregnancy * Anaemia, haemoglobin \< 7.3 mmol/l (women) or \< 8.3 mmol/l (men)

What they're measuring

Borg dyspnea score

Timeframe: At baseline and through completion (one day)

Trial details

NCT IDNCT06465654

SponsorJanne Hastrup Jensen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-10